Zusammenfassung
Obwohl aktuelle Studien, nationale und internationale Leitlinien feststellen, dass die strikte Kontrolle der Risikofaktoren für die Vermeidung des Fortschreitens einer arteriosklerotischen Krankheit von zentraler Bedeutung ist, werden Statine, ACE-Hemmer, β-Blocker und Thrombozytenaggregationshemmer nicht routinemäßig bei Patienten mit peripherer arterieller Verschlusserkrankung (pAVK) eingesetzt. Sogar Patienten mit einem hohen Risiko bei zusätzlichem Diabetes mellitus erhalten z. B. Statine in weniger als 70% der Fälle. Die Tatsache, dass eine nachhaltige Verbesserung der medikamentösen sekundären Prophylaxe bei Patienten mit arteriosklerotischen Erkrankungen des Herzens möglich ist, sollte die Optimierung der medikamentösen Sekundärprophylaxe bei Patienten mit pAVK zur Folge haben, die aktuell noch unzureichend ist.
Abstract
Although current studies as well as national and international guidelines state that strict control of risk factors is crucial in the prevention of progression of atherosclerotic disease, statins, ACE inhibitors, beta blockers and platelet aggregation inhibitors are not routinely administered in patients with peripheral arterial occlusive disease. Even high risk patients with additional diabetes receive for example statins in less than 70% of cases. The fact that improving secondary medical prophylaxis for patients with atherosclerotic disease of the coronary arteries is possible should encourage the optimization of medical prophylaxis of patients with peripheral arterial occlusive disease, which is currently insufficient.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Anonym (1994) Antiplatelet Trialists‘ collaboration collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106. Erratum in: BMJ 308:1540
Anonym (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253–259. Erratum in: Lancet 2000;356:860
Anonym (2002) Antithrombotic Trialists‘ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86. Erratum in: BMJ 324:141
Aronow WS, Nayak D, Woodworth S, Ahn C (2003) Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 92:711–712
Bianchi C, Montalvo V, Ou HW et al (2007) Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 21:163–166
Böhner H, Balzer K, Nowak T (2008) Medikamentöse Therapie nach gefäßchirurgischen Operationen und endovaskulären Interventionen. http://www.uni-duesseldorf.de/awmf/ll/004-030.htm:446–457
Burns P, Lima E, Bradbury AW (2002) Second best medical therapy. Eur J Vasc Endovasc Surg 24:400–404
Caprie Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348:1329–1339
Cavender JB, Rogers WJ, Fisher LD et al (1992) Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. J Am Coll Cardiol 20:287–294
Domburg RT van, op Reimer WS, Hoeks SE et al (2008) Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J 156:473–476
Fatourou EM, Paraskevas KI, Seifalian AM et al (2007) The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother 8:901–911
Gasse C, Jacobsen J, Larsen AC et al (2008) Secondary medical prevention among danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg 35:51–58
Giri J, McDermott MM, Greenland P et al (2006) Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 47:998–1004
Goessens BM, Graaf Y van der, Olijhoek JK, Visseren FL (2007) SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 45:47–54
Heart Protection Study Collaborative Group (2007) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45:645–654
Hirsh AT, Haskal ZJ, Hertzer NJ et al (2006) AHA/ACC Guidlines for the management of patients with peripheral arterial disease(lower extremity, renal, mesenteric, and abdominal aortic). J Am Coll Cardiology 47:1–192
Hoogwegt MT, Hoeks SE, Pedersen SS et al (2010) Smoking cessation has no influence on quality of life in patients with peripheral arterial disease 5 years Post-vascular surgery. Eur J Vasc Endovasc Surg ahead of print
Interdisziplinäre Leitlinie „Diagnostik und Therapie der peripheren arteriellen Verschlußkrankheit“ AWMF 065-003. http://leitlinien.net
Jankowski P, Kawcka-Jaszcz K, Pajak A et al (2009) Secondary prevention of coronary heart disease in hospital practice over the decade 1996–2006. Results of the cracovian program for secondary prevention of ischemic heart disease and polish parts of the EUROPASPIRE II and EUROPSPIRE III surveys. Kardiol Pol 67:970–976
Kahn S, Flather M, Mister R et al (2007) characteristics and treatments of patients with peripheral arterial disease referred to UK Vascular Clinics: results of a prospective registry. Eur J Vasc Endovasc Surg 33:442–450
Margeta C, Giurgea A, Hammer A et al (2009) Impact of international guidelines on the management of cardiovascular risk factors in diabetic patients with peripheral arterial disease. Int Angiology 28:175–180
McDermott MM, Guralnik JM, Greenland P et al (2003) Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107:757–761
Mohler ER 3rd, Hiatt WR, Creager MA (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108:1481–1486
Mondillo S, Ballo P, Barbati R et al (2003) Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114:359–364
Norgren L, Hiatt WR, Dormandy JA et al (2007) TASC II Working Group. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45(Suppl S):S5–67
Silber S et al (2005) Guidelines for percutaneous coronary interventions. The force for percutaneous interventions of the European society of cardiology. Eur Heart J 26:804–847
Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372.Erratum in: Circulation;113:e847
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klein-Weigel, P., Böhner, H. Medikamentöse Therapie zur Sekundärprophylaxe bei pAVK. Gefässchirurgie 16, 338–341 (2011). https://doi.org/10.1007/s00772-011-0877-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00772-011-0877-3